Bone metastases cause significant morbidity and mortality in late-stage breast cancer patients and are currently considered incurable. Investigators rely on translational models to better understand the pathogenesis of skeletal complications of malignancy in order to identify therapeutic targets that may ultimately prevent and treat solid tumor metastasis to bone. Many experimental models of breast cancer bone metastases are in use today, each with its own caveats. In this methods review, we characterize the bone phenotype of commonly utilized human-and murine-derived breast cell lines that elicit osteoblastic and/or osteolytic destruction of bone in mice and report methods for optimizing tumor-take in murine models of bone metastasis. We then provide protocols for four of the most common xenograft and syngeneic inoculation routes for modeling breast cancer metastasis to the skeleton in mice, including the intra-cardiac, intra-arterial, orthotopic and intra-tibial methods of tumor cell injection. Recommendations for in vivo and ex vivo assessment of tumor progression and bone destruction are provided, followed by discussion of the strengths and limitations of the available tools and translational models that aid investigators in the study of breast cancer metastasis to bone.
Introduction
Breast cancer metastasis to the skeleton and subsequent bone destruction often result in severe bone pain, fragility fractures, nerve compression syndromes and hypercalcemia of malignancy resulting in significant morbidity and mortality. 1, 2 Elucidation of the molecular mechanisms that mediate breast cancer bone metastases and cancer-induced bone destruction has begun to reveal potential therapeutic targets that may lead to improved patient survival and quality of life; however, further investigation is necessary to address this currently irreversible late-stage complication of malignancy. Therefore, it is of utmost importance for investigators to establish well-characterized in vivo models of breast cancer bone metastasis.
Unlike the study of postmenopausal osteoporosis where the ovariectomy model is the clear FDA-mandated choice, 3 there are numerous murine models of breast cancer metastasis to bone, each with its own benefits and limitations. Because spontaneous metastasis to the skeleton from primary tumors in animals is rare, 2 and no single model reproduces all of the genetic and phenotypic changes of human breast cancer bone metastasis, researchers must select a model or a combination of models that best suits the aspect of the metastatic disease that they wish to investigate. Here we (1) identify the most commonly utilized breast cancer cell lines that elicit osteolytic, osteoblastic or mixed phenotypes in bone, (2) provide protocols for tumor cell inoculation routes that model metastatic disease in the skeleton and (3) explore methods for the post-inoculation monitoring of breast cancer progression in bone.
Modeling osteolytic breast cancer bone metastases
Inoculation of bone trophic tumor cells directly into the blood stream provides a useful tool for investigating the processes associated with breast cancer cell homing, colonization and subsequent metastatic tumor growth and osteolytic lesion formation in bone. Intra-cardiac inoculation of human triple negative MDA-MB-231 adenocarcinoma cells into immunecompromised mice (i.e., BALB/c nude, MF1 nude and NOD/SCID) results in tumor cell dissemination through the arterial vascular system and homing primarily to long bones, spine, jaw and lungs ( Figure 1a ; Table 1 ). 4, 5 In syngeneic tumor models where murine-derived cell lines are inoculated into a murine host, a bone metastatic profile can be observed with varying degrees of success following intra-cardiac injection of 4T1 or PyMT MMTV mammary cancer cells into immune competent BALB/c or FVB/N mice, respectively ( Table 1) . 6, 7 Visceral metastases, particularly to the lung, can significantly shorten the life span of a mouse and thus limit the experimental time frame during which skeletal metastases can be studied in vivo. MDA-MB-231 and 4T1 cell lines have therefore been manipulated in the laboratory to produce bone-seeking sub-lines that favor homing to and colonization of mouse tibiae and femurs with a reduced propensity to metastasize to the lung. Bone-seeking sub-lines, often referred to in the literature as MDA-MB-231-B02, MDA-MB-231-1833, MDA-MB-231-B, MDA-IV and MDA-MB-231-bone, form tumors in the long bones of up to 90% of mice following intra-cardiac inoculation in BALB/c nude mice. [8] [9] [10] [11] [12] Intra-cardiac inoculation of the subline 4T1-2 cells into BALB/c mice results in bone metastases in 70-80% of animals ( Table 1) . 13 Direct intra-tibial injection of a number of breast cancer cell lines including MDA-MB-231, MDA-MB-436 and SUM1315 into immunocompromised mice and 4T1 and PyMT MMTV cell lines into immune competent BALB/c and FVB/N mice results in the development of osteolytic mammary tumors in bone with minimal impact outside of bone marrow engraftment ( Figure 1b ; Table 1) . 7, 14, 15 The intra-tibial model bypasses the early stages of metastasis including homing to the bone microenvironment and is therefore useful for a more direct assessment of tumor-bone interactions, particularly when interested in studying genetic manipulations of the host or tumor cells of interest.
Intra-cardiac, intra-arterial and intra-tibial inoculation of cancer cells provide useful tools for examining the later stages of breast cancer bone metastasis; however, these aforementioned models do not permit investigation into the stages that precede the colonization of breast cancer in bone, including primary tumor growth or the dissemination of tumor cells through intravazation. The 4T1 mouse mammary cancer cell line was derived from a BALB/c spontaneous mammary carcinoma, 16 
and orthotopic inoculation of 4T1 cells into the
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Intra-tibial 4T1 Intra-tibial MCF-7 Figure 1 Radiographs of the distal femur and proximal tibia of mice with breast cancer bone metastases. Representative images are presented of (a). MDA-MB-231 breast cancer bone metastases 4 weeks post inoculation of 100 000 cells via intra-cardiac route, (b). ZR-75-1 breast cancer bone metastases 25 weeks post inoculation of 100 000 cells via intra-cardiac route, (c). 4T1 breast cancer bone metastases 4 weeks post inoculation of 10 000 cells via intra-tibial route, and (d). MCF-7 breast cancer bone metastases 20 weeks post inoculation of 100 000 cells via intra-tibial route.
Modeling breast cancer bone metastases in mice LE Wright et al mammary fat pad of BALB/c mice results in spontaneous metastasis to lungs (B60% of mice) and bone (B20-30% of mice; Table 1 ). 17 Incidence of bone metastasis can be increased to 50-70% by utilizing the bone-seeking 4T1-2 subline. 18, 19 This syngeneic model has the benefit of utilizing an immune competent mouse.
Recently, it was shown that orthotopic inoculation of luciferase-transduced murine invasive lobular breast carcinoma cells (KEP cells) resulted in the formation of bone metastases in the appendicular and axial skeleton within 3 weeks after resection of the orthotopic tumor with minimal lung involvement in BALBc nude mice ( Table 1) . 20 Although MDA-MB-231 do not metastasize to murine bone from the orthotopic site in BALB/c nude and NOD SCID mice, distant metastases at skeletal sites were observed when using NSG mice, 21 suggesting the importance of NK cells in regulating the metastatic process.
Spontaneous metastasis of an orthotopic human breast cancer tumor to bone can be achieved in an immunecompromised mouse using a unique model that incorporates human-derived bone X-plants. In recent studies, orthotopic inoculation of human-derived SUM-1315 or MDA-MB-231-IV cells into the mammary fat pad of NOD SCID mice 4 weeks following ectopic implantation of human bone resulted in spontaneous metastasis of human breast cancer cells specifically to the human bone grafts in 40-60% of animals ( Table 1) . 22, 23 Modeling osteoblastic breast cancer bone metastases Although patients with breast cancer usually develop osteolytic bone metastases, as many as 25% will present with osteoblastic bone metastases. 24 The human breast cancer cell lines ZR-75-1 and MCF-7 can be utilized to establish an osteoblastic bone metastatic phenotype in mice.
ZR-75-1 cultures were initially derived from a malignant ascetic effusion in a 63-year-old Caucasian female with ductal carcinoma. ZR-75-1 cells possess receptors for all four classes of steroid hormones and are thus responsive to estradiol stimulation. 25, 26 Mice inoculated via intra-cardiac route with ZR-75-1 cells develop osteoblastic bone metastases in the long bones; however, bone metastases are typically not detectable by X-ray for 12-25 weeks post inoculation ( Figure 1c ; Table 2 ). Human MCF-7 breast cancer cells were derived from a metastatic pleural effusion in a 69-year-old Caucasian female with breast carcinoma. 27 MCF-7 cells retain characteristics of differentiated mammary epithelium and possess estrogen receptors. 27, 28 Intra-cardiac inoculation of MCF-7 cells in immune-compromised mice results in mixed osteolytic/ osteoblastic bone metastases in the long bones after 20-25 weeks ( Table 2 ). In order to speed metastatic progression, the MCF-7 cell line has been stably transfected with the oncogene Neu, and this cell line establishes mixed osteolytic and osteoblastic bone metastases in immunocompromised mice within 10-12 weeks after intra-cardiac inoculation. 29 Because ER þ MCF-7 cell growth is estrogen dependent mice should be implanted subcutaneously with slow-release estradiol pellets (0.25 mg) prior to intra-cardiac tumor cell inoculation in order to more closely mimic a pre-menopausal tumor environment and speed the progression of tumor growth in bone. 30, 31 MCF-7 and MCF-7/Neu cells are also commonly utilized to establish bone lesions in mice via the intra-tibial inoculation route, with lesions developing in a shorter time span of 1-3 weeks post injection ( Figure 1d ; Table 2 ). Estradiol supplementation is typically not introduced when MCF-7 cells are directly implanted into bone.
Materials and Methods
This section begins by detailing recommendations for the preparation of breast cancer cells and pre-operative care instructions for the handling of mice prior to inoculation. Four of the most commonly utilized cell inoculation routes resulting in breast cancer bone metastases are then described, including lists of necessary materials for each technique. Recommendations for the post-inoculation monitoring of animals and assessment of tumor progression in bone in vivo and post mortem are then described.
Breast cancer cell preparation
Manufacturer specifications should guide the user as to the appropriate growth conditions for the cell line of interest. As a general rule for all tumor cell inoculation routes, prepare cells from a fresh batch of low passage number. Split cells 1-2 days prior to the injections such that they reach B80% confluence on the day of inoculation. Overcrowding of tumor cells can affect their metastatic potential in vivo; therefore, cell confluence prior to inoculation must be monitored judiciously. Wash flasks briefly with the appropriate cold cell culture media or phosphatebuffered saline (PBS), trypsinize (0.15% Trypsin EDTA) at 37 1C, and remove cells with ice-cold media containing 10% fetal bovine serum (FBS). Centrifuge (200 g, 5 min) and suspend the cell pellet in ice-cold PBS for quantitation. Re-suspend the cells at the desired concentration ( Table 3 ) in cold PBS and keep the cell suspension for no more than 30 min on ice until the moment of inoculation. Prepare cells in small batches (enough for 1-2 cages or 5-10 animals) and keep on ice to minimize clumping and risk of embolism during the in vivo inoculation.
Because of volumetric limitations of the mouse circulation 100 ml is the recommended injection volume using the intra-cardiac or intra-arterial routes.
Reagents for tumor cell preparation
Pre-operative management of mice
For the intra-cardiac, intra-arterial and intra-venous metastasis models, mice are inoculated between 4 and 6 weeks of age, as tumor-take is markedly reduced after 6 weeks. For the intra-tibial injection, 6-to 8week-old mice are typically used, as tibiae of younger mice are small and difficult to inject accurately. A ketamine/xylazine cocktail (100 mg kg À 1 and 10 mg kg À 1 , respectively) or isoflurane (2.5% isoflurane at 2-3 l min À 1 O 2 ) may be utilized for anesthesia during the inoculation of tumor cells depending on the laboratory's preference. Many groups, however, experience improved survival rates following intra-cardiac inoculation with the use of isoflurane (vs ketamine/ xylazine), likely due to increased vascular tone and body temperature. If the mouse strain selected is furred, it may be important to shave the mouse at the site of inoculation for better visualization of anatomical landmarks.
Cellular inoculation routes for modeling breast cancer bone metastases in mice
Intra-cardiac inoculation of breast cancer cells. Once a mouse has been properly anesthetized and is unresponsive to pinch, place it on a sterile surface in supine position ensuring that the vertebral column is straight. Tape the forelimbs away from the torso at a slightly angled and upward position (Figure 2a ). Prior to inoculation, clean the chest of the animal thoroughly with betadine and wipe with an alcohol pad or as per the institutional standard operating procedures. Once the chest has been sterilized, gently place one hand on the chest of the mouse to tighten the skin and mark the top of the sternum and the xyphoid process (distal sternum) with a permanent marker (Figure 2a ). Make a third mark in the middle of these two landmarks and slightly to your right (animal's left) just over the heart in the third intercostal space (Figure 2a ). This mark identifies the location of the left cardiac ventricle where you will insert the needle for tumor cell inoculation.
With intra-cardiac inoculation, prepare the needle by leaving a small air space in the top of the syringe before slowly drawing up the desired volume of cell suspension into the syringe (Figure 2b ). This air space will permit a small influx of bright red oxygenated blood into the syringe hub when properly inserted into the left cardiac ventricle. Hold the skin of the mouse tight with one hand and insert the needle perpendicularly into the middle marking ( Figure 2c ). When the needle has entered the left cardiac ventricle, watch for the pulse of blood to appear in the hub of the needle. The appearance of air bubbles in the needle hub upon insertion indicates that it has likely entered the lungs and will need to be removed and repositioned. If you do not see a red pulse of blood in the needle hub but are confident that you are in the correct location, you can pull up slightly on the syringe plunger to verify your position in the cardiac ventricle. If there is still no visible red pulse, the needle can be slowly and slightly adjusted up or down. When small adjustments are futile, remove and reposition the insertion point completely or set the mouse aside temporarily. Extended anesthesia can cause vasoconstriction and reduce the animal's blood pressure such that the pulse of blood into the needle's hub becomes less noticeable. Once the needle is correctly positioned in the left cardiac ventricle, inject the cell suspension slowly into the left ventricle being careful not to move the needle or press it deeper into the thoracic cavity. Keep a close eye on the cell suspension in the syringe and do not inject the air bubble at the top of the syringe (Figure 2b) . As soon as the cells have been inoculated, quickly remove the needle, apply slight pressure at the injection site for a few seconds and place the mouse on a heating pad until fully awake. Once mice have fully recovered, monitor their behavior for 24 h and watch for potential signs of embolism or distress.
Materials for intra-cardiac inoculation the table for stability. Use a heating pad or lamp to dilate the vessels within the tail for 2-3 min in order to facilitate greater ease of inoculation. Alternatively, the tail can be placed in warm water (30-35 1C) . Using an alcohol pad, disinfect the tail vigorously, which will also help dilate the vessels within the tail and facilitate inoculation. Keep the tail clinched between the forefinger and thumb and insert the needle (beveled edge facing up) horizontally across the proximal section of the tail into the artery (Figure 3) . Once the needle has entered the artery, the opposite hand is used to retract the syringe plunger slightly to inspect for a tight fitting within the artery and inspect the barrel of the syringe for a small amount of blood, which should appear at the needle hub. This will not occur if the needle has not breached the epithelial membrane of the artery or if the syringe has protruded through the artery. Once the syringe is properly Orthotopic (mammary fat pad) inoculation of breast cancer cells.
Place an anesthetized mouse in supine position on a sterile surface and tape the forelimbs and hind limbs away from the torso (Figure 4a ). Prior to inoculation, clean the inguinal surface of the animal thoroughly with betadine and wipe with an alcohol pad or as per the institutional standard operating procedures. Using sterile surgical instruments, create a small incision in the skin adjacent to the fourth mammary fat pad (Figures 4b and c) . Insert the needle into the fourth mammary gland fat pad and slowly inoculate the tumor cell suspension (Figures 4d and e ; Supplementary Video 1). The 4th mammary gland fat pad is located at the intersection of three prominent blood vessels (Figure 4c) . As with all techniques, it may be important for investigators to practice and familiarize themselves with the necessary anatomical landmarks prior to initiation of a multi-animal study. After the injection of cells, close the wound with 4-6 unconnected sutures, administer an analgesic as per institutional guidelines and place the mouse on a heating pad until fully awake.
In order to limit the occurrence of spontaneous tumor metastases to the lungs when using murine-derived cells (for example, 4T1), primary tumors can be surgically resected from anesthetized mice when tumors reach B1 cm 3 . Animals can then be followed for 3-4 additional weeks for the development of bone metastases.
Some laboratories have reported that orthotopic implantation of the human-derived breast cancer cell lines SUM-1315 and MDA-MB-231-IV into immune-compromised mice can elicit spontaneous metastasis to bone when preceded by engraftment of human bone plugs. 22, 23 In this model, 5 mm bone biopsy cores obtained from human femoral heads (within 2-4 h of removal from the patient) can be implanted under the skin on the posterior surface of the animal prior to tumor cell inoculation in the mammary fat pad. Four weeks after bone plug implantation, the human bone grafts become vascularized and bone marrow resembles that of normal bone. 22, 23 Orthotopic injection of human-derived tumor cells can then proceed as described, and the human bone plugs are then excised at the termination of the study (B8-14 weeks) and evaluated for the presence of breast cancer metastases.
Materials for orthotopic inoculation Ligament Figure 5 Inoculation of breast cancer cells in the proximal tibia of a mouse. (a) After sterilizing the hind limbs of an anesthetized mouse, bend the knee to nearly 901. While holding the hind limb between the thumb and index finger, locate the patellar ligament between the knee and the tibia, which should be visible through the skin as a white longitudinal structure. (b) Holding the needle parallel to the tibia in the dominant hand, push the needle through the center of the patellar ligament and into the proximal end of the tibia. Resistance will be felt once the needle reaches the bone. Twist the needle slightly to drill through the growth plate until the needle can be felt giving way. Once inserted into the bone approximately 2-3 mm, inject the cell suspension slowly and then withdraw the needle using the same drilling motion used to enter the bone.
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Intra-tibial inoculation of breast cancer cells. Prepare a syringe with the desired tumor cell suspension and set aside until ready to inject. After sterilizing the hind limbs, bend the knee to nearly 901 (Figure 5a) . While holding the hind limb between the thumb and index finger, locate the patellar ligament between the knee and the tibia, which should be visible through the skin as a white longitudinal structure. Some laboratories choose to make a 2-3 mm incision through the skin on the knee to more easily visualize the tibia and patellar ligament; however, with practice this may not be necessary. Holding the needle parallel to the tibia in the dominant hand, push the needle through the center of the patellar ligament and into the proximal end of the tibia (Figure 5b) . Resistance will be felt once the needle reaches the bone. Twist the needle slightly to drill through the growth plate until the needle can be felt giving way. Once inserted into the bone B2-3 mm, attempt to move the needle slightly from side to side. When the needle is in the tibia, it will not be easily moved. If it moves freely from side to side, the needle is most likely embedded primarily in muscle and the insertion will need to be repeated. When the needle is accurately placed inside the marrow cavity of the tibia, inject the cell suspension slowly and then withdraw the needle using the same drilling motion used to enter the bone. In the event that the needle becomes clogged when penetrating or drilling through the top of the tibia, remove the original needle and re-insert a new needle, trying to follow the route created by the first needle. Once complete, use the same technique to inject the contralateral tibia with sterile PBS or desired vehicle to serve as a sham control. Bleeding rarely occurs; however, if blood does appear, apply pressure at the site.
Administer an analgesic as per institutional guidelines, place the mouse on a heating pad and monitor until active.
Although cells can be inoculated into the tibia at any age, it is more difficult to penetrate the tibia in older animals once the growth plates have mineralized (48-week old). On the other hand, very young mice can present injection difficulties due to the small size of the tibia; most laboratories therefore select 4-to 6-week-old mice for the intra-tibial inoculation route. If the mouse strain selected is furred, shave or wet the hair on the hind limb prior to the inoculation in order to better visualize the patellar ligament and other landmarks in the knee.
Materials for intra-tibial inoculation 
Assessment of tumor progression in bone
Throughout a bone metastasis experiment, mice should be monitored daily for changes in activity levels, mobility and onset of cachexia, which is a paraneoplastic syndrome characterized in mice by loss of body weight, muscle atrophy and weakness, arched appearance and lethargy. 32, 33 Mice should be euthanized when 410-20% body weight is lost, tumor progression impairs mobility (for example, long bone fracture, head-tilt, paraplegia) or an animal appears to be in respiratory distress. A subset of mice may require euthanasia sooner than other mice in large studies. With the exception of survival studies, it is important that mice be euthanized on the same day or as close to the same day as possible such that the experimental time frame is identical for all mice, thus permitting an accurate comparison of tumor progression between groups. Osteolytic lesion area and abnormal bone remodeling can be visualized and assessed weekly in vivo using a cabinet X-ray machine (Figure 6a ; Table 4 ). Because X-ray analysis is an assessment of overt osteolytic lesion formation and provides only indirect information on tumor cell growth, cancer cell lines are commonly transfected with bioluminescent proteins permitting in vivo visualization and quantitation of tumor growth at metastatic sites using bioluminescence imaging (BLI ;  Table 4 ). 11, 20, 34 BLI serves as an ideal complement to X-ray analysis of osteolysis, as it provides information on the presence of extra-skeletal metastases as well as micrometastases in bone, which precede bone destruction. Although not utilized to quantitate skeletal tumor burden, intra-vital microscopy may be useful for studying individual tumor cell motility and behavior in the bone microenvironment. 35 At the termination of the study, mice should be subjected to necropsy and examined closely for gross evidence of metastatic foci outside of bone. For an intra-cardiac tumor inoculation study, evidence of tumor growth in the mediastinum surrounding the heart indicates that tumor cells were not accurately injected into the left cardiac ventricle, and the mouse should be excluded from the study. Fix all vital organs for future analysis. Carefully cut and scrape away skeletal muscle from the forelimbs, hind limbs and vertebral column, and fix the skeletal samples. Prior to decalcification of the bones, high-resolution ex vivo bone microcomputed tomography (mCT) can be performed to assess osteolytic or osteoblastic bone destruction and BV/TV at the distal femur, proximal tibia or lumbar vertebrae (Figure 6b) .
Following decalcification, paraffin-embedded bone should be sectioned and stained with hematoxylin/eosin (H&E), and tumor burden (mm 2 ) should be measured in long bones and spine using image analysis software (Figure 6c) . Osteoblast numbers may also be quantitated in H&E stained sections. Histological sections should also be stained for tartrate-resistant acid phosphatase activity in order to assess the total osteoclast number relative to the bone surface and the osteoclast number at the bone and tumor interface, all of which are known to increase with cancer-induced osteolysis (Figure 6d ; Table 4 ). [36] [37] Finally, serum can be assayed for the presence of bone turnover markers, hormones, inflammatory factors or growth factors of interest.
When applicable, quantification of spontaneous metastases to lung, liver, brain or adrenals can be performed in paraffin-embedded organs collected at necropsy. For these analyses, 5 mm sections can be cut every 200 mm through the organ and stained with H&E. The number and area of metastatic foci for each section can then be determined using image analysis software, and results can be expressed as the total metastatic foci number per organ and as total metastatic area per organ.
Discussion
When considering skeletal metastasis models with the intention of studying breast cancer osteolysis, a common choice is the intra-cardiac injection of human breast cancer cells in immunecompromised mice. [38] [39] [40] Alternatively, these human cells can be directly implanted into bone, bypassing earlier steps in the metastatic process. A benefit of the former model is that tumor cells detected in bone have themselves 'seeded the soil,' thus replicating the more natural progression of disseminated tumor cells formation of micrometastases, which progress in size over time, as occurs in humans. The necessity of using immune cell-deficient mice when inoculating human cell lines is typically seen as a limitation because it does not accurately model the immune competent human patient. It can, however, be seen as an advantage, as it eliminates possible confounding effects related to the animal's immune response and permits the study of human cells in a very permissive host environment.
The pathogenesis of breast cancer bone destruction in the intra-cardiac MDA-MB-231 model is relatively similar to the human condition. Upon inoculation, breast cancer cells circulate in the vasculature, home to the bone compartment, and micrometastases can be detected by BLI in distant skeletal sites in as early as 1 week after injection. 41 As the tumor cells proliferate in the bone microenvironment, tumor-derived Modeling breast cancer bone metastases in mice LE Wright et al osteolytic factors stimulate osteoclastic bone resorption and the development of bone lesions, which are quantifiable by X-ray. The most substantial bone destruction tends to occur in the metaphyses of the distal femur and proximal tibia, likely due to the high vascularization and metabolic activity characteristic of these trabecular bone compartments. 42 Estrogen receptor (ER) þ MCF-7 cells and triple negative MDA-MB-231 cells are two of the most commonly studied human breast cancer cell lines. 40 Although ER þ primary tumors have a high propensity to metastasize to bone in patients, 43 ER þ MCF-7 cells are utilized less frequently in models of breast cancer bone metastasis, as tumor-take can be limited using the intra-cardiac inoculation route, and MCF-7 cells require a longer time to develop osteolytic and osteoblastic lesions. 44, 45 In contrast, ER À MDA-MB-231 cells readily metastasize to bone and develop osteolytic lesions as early as 2-3 weeks post inoculation. 39 In defense of the use of an ER À cell line, it should also be noted that there is a large discordance between the ER status of primary tumors and the ER status of the bone metastatic tumors in patients. 43 The intra-tibial inoculation method is ideal for modeling the final stages of breast cancer bone metastasis and for studying direct interactions between tumor cells and the bone microenvironment without concerns about differential tumor-take from animal to animal. Murine-derived 4T1 cell proliferation in the tibia and subsequent development of osteolytic lesions can occur with the injection of as few as 10 000 murine-derived cells. At higher cellular concentrations (50 000-200 000 cells), our laboratories have observed 4T1 cell metastasis to contralateral tibiae, femurs, forelimbs and the lungs, often limiting the duration and utility of the model. As with all techniques presented here, it is recommended that investigators thoroughly characterize their cell line and inoculation route of choice by conducting dose-response studies in order to establish the optimal protocols prior to embarking on large animal trials.
Inoculation of cancer cells into the tail vein is a wellestablished bone metastasis model for multiple myeloma. 46, 47 Our laboratories and others have found that the injection of breast cancer cells into the tail vein results almost exclusively in lung metastases, with limited tumor-take in bone. 22, 48 When skeletal metastases are desired, we therefore recommend utilization of the tail artery as the tumor inoculation route for breast cancer models. 22, [48] [49] [50] [51] [52] In addition to specific limitations related to model choice discussed above, standard methodologies used by bone metastasis researchers to assess bone destruction and tumor burden have their own limitations. Osteolytic lesion area and tumor burden area in bone are typically assessed by measurement of X-Ray scan or by serial histological sectioning, respectively, and are thus merely two-dimensional approximations of three-dimensional tumors. Improvement in imaging has enhanced sensitivity of detection and yields more accurate Intra-cardiac 100 000 100 ml 0.5-1 cc insulin/27-29G, 0.5 inch Intra-arterial (tail) 100 000 100 ml 0.5-1 cc insulin/7-29G, 0.5 inch Orthotopic 100 000-5 00 000 10-20 ml 0.1 cc Hamilton/25-27G, 0.5 inch Intra-tibial 10 000-2 50 000 10-20 ml 0.1 cc Hamilton/25-27G, 0.5 inch
Modeling breast cancer bone metastases in mice LE Wright et al quantification of metastases. Typically, BLI using codonoptimized luciferase-labeled cells yields higher detection than fluorescent imaging using GFP-labeled cells. 53 Small animal imaging of bone has forged ahead with the development of high-resolution in vivo mCT scanners 54 in combination with BLI. 55 However, the bone metastasis research community has been slower to adopt such methodologies. One reason for this is that cumulative radiation exposure from CT scanners has been found to enhance metastases 56 and thus could confound cancer metastasis models if radiation exposure is not monitored judiciously.
Despite their limitations and caveats, the established murine models of breast cancer bone metastases have proven to be excellent tools for the study of bone and cancer cross talk and for the evaluation of potential therapeutics that prevent cancer progression and disrupt the cycle of bone destruction driven by metastasis.
Multimedia
The following article documents and visually demonstrates intra-cardiac and intra-tibial inoculation of cancer cells in mice and also demonstrates representative experimental end points of bone metastasis: http://www.jove.come/video/4260.
